Healthy Subjects
Conditions
Interventions
Group 1: Intervention (Cross-Over):
Placebo:
water colored with yellow food coloring
Intervention 1:
LCT: 0,5 g/kg body weight
Intervention 2:
LCT: 0,5 g/kg body weigh
Glucose 0,2 g/kg body weight
Intervention 3:
100 % MCT oil: 0,5 g/kg body weight
Intervention 4:
100 % MCT oil: 0,5 g/kg body weight
Glucose 0,2 g/kg body weight
Sponsors
Dr. Schär AG/SPA
Eligibility
Sex/Gender
All
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Age between 18 - 35 years Male, female (equal distribution) No diagnosed metabolic disease (e.g. lipid metabolism disorder, diabetes mellitus type 1 or 2) not taking any medication (exception: contraceptives) No chronic health impairment (e.g. cardiovascular diseases, thyroid defects, intestinal diseases), Normal weight (BMI = 18.5 - 25.0), No mental or speech impairments, No low carb, vegan or other diet with permanent reduction of carbohydrate intake (DGE requirement: min. 50 %KH) Signature of informed consent
Exclusion criteria
Exclusion criteria: No MCT/Coconut oil supplements Pregnancy/breastfeeding Simultaneous participation in other studies/study programmes Taking medication Severe underlying disease (e.g. cancer) Mental illness (e.g. depression, schizophrenia) Existing metabolic disease Chronic illness (see above) Overweight/obesity (BMI = > 25.0) Not meeting the DGE guidelines for a healthy mixed diet (< 50 % KH/day) Blood donation within the last 3 months before the start of the study Intolerance to emulsifiers (lecithin, soy) and sweeteners (cyclamate, thaumatin, aspartame)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the concentration of the ketone body beta-hydroxybutyrate (BHB, in mmol/L) between the maximum BHB concentration and the BHB concentration at the beginning of the measurement. The primary aim is to prove that glucose intake causes a change in the primary endpoint. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychological testing Testing of cognitive performance during the intervention Interview on hunger and fullness during the intervention Sensory testing Questionnaire on smell, taste and mouthfeel of the product during the intake phase Anthropometric data Weight, height, calculation of BMI Vital signs Blood pressure, pulse Blood parameters Carbohydrate metabolism: Insulin, glucose Acid-base balance: Osmolarity, osmolality, magnesium, calcium, blood gas analysis (BGA)*. * pH, pCO2, pO2, bicarbonate, ABEc, sodium, potassium, cBase (Ecf), chloride, calcium, anion gapc, anion gap Kc, glucose, lactate, p50, p50 (st), ctHb, FO2Hb, FCOHb, FMetHb, FHHb, Hctc. Ketone bodies: Acetoacetate, ß-hydroxybutyrate (ßHB). Fatty acids: essential and non-essential fatty acids. Other parameters Urine | — |
Countries
Germany
Contacts
Public ContactThorsten Marquardt
Universitätsklinikum MünsterAbteilung für angeborene StoffwechselerkrankungenAlbert-Schweitzer-Campus 1 / Geb. A1348149 Münster
Outcome results
None listed